15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering ResMed Inc, 3 rate it Buy or better, 9 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $215.00 to $275.00, so the covering firms are broadly aligned. The average target of $239.18 sits 8% above the current $221.06. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $3.04 next quarter toward $13.21 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Moderate Buy
Strong Buy00%
Buy325%
Hold975%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to ResMed Inc.
As of Sep, 3 of 12 firms rate RMD a Buy (9 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RMD EPS & revenue forecast
EPS · NEXT QUARTER
$3.04
Range $2.99 – $3.11 · 13 analysts · +8% YoY
Next period, 13 analysts expect ResMed Inc to earn $3.04 a share (range $2.99 – $3.11), versus $2.81 a year earlier. Full-year consensus is $12.08, growing to $13.21 the year after.
REVENUE · NEXT QUARTER
$1.5B
Range $1.4B – $1.5B · 13 analysts · +2% YoY
Revenue is expected to reach $1.5B (range $1.4B – $1.5B), +2.0% year-over-year. Full-year consensus is $5.8B, rising to $6.2B next year.
Top analysts covering ResMed Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RMD.
#1
Anthony Petrone
Mizuho · Rank #86
Buy
$220.00-0.5% to target
Overall win rate
46%
+ Follow
#2
Jonathan Block
Stifel · Rank #205
Hold
$235.00+6.3% to target
Overall win rate
41%
+ Follow
#3
Justin Patterson
Keybanc · Rank #400
Buy
$266.00+20.3% to target
Overall win rate
26%
+ Follow
#4
CW
Craig Wong-Pan
RBC Capital
Hold
$244.00+10.4% to target
Coverage
—
+ Follow
#5
Brett Fishbin
KeyBanc
Buy
$267.00+20.8% to target
Coverage
—
+ Follow
RMD stock forecast FAQ
What is RMD's average 12-month price target?+
The 11 analysts with a live target average $239.18 for ResMed Inc over the next 12 months, ranging from a $275.00 high to a $215.00 low.
Is RMD stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 12 analyst ratings, 3 are Buy or Strong Buy, 9 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RMD?+
The Street-high target is $275.00 (Baird), and the Street-low is $215.00 (Wells Fargo). The average of all 11 active targets is $239.18.
How many Wall Street analysts cover RMD?+
12 analysts have an active rating on ResMed Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering RMD?+
Among analysts who currently cover RMD, Anthony Petrone of Mizuho has the strongest overall Quantellect track record (Rank #86). Their current call is Buy with a $220.00 target.
What is ResMed Inc's projected EPS for next quarter?+
The consensus estimate is $3.04 per share (range $2.99 – $3.11) across 13 analysts. Full-year EPS is projected at $12.08, rising to $13.21 the following year.
How much revenue is ResMed Inc expected to report next quarter?+
Consensus revenue is $1.5B (range $1.4B – $1.5B). Full-year revenue is projected at $5.8B, growing to $6.2B next year.
Have analysts been upgrading or downgrading RMD lately?+
As of Sep, 3 of 12 firms rate RMD a Buy (9 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
